世界の未分化星細胞腫市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)

GlobalInfoResearchが発行した調査報告書(GIR20SP12417)
◆英語タイトル:Global Anaplastic Astrocytoma Market 2020 by Company, Regions, Type and Application, Forecast to 2025
◆商品コード:GIR20SP12417
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2020年9月25日(※2024年版があります。お問い合わせください。)
◆ページ数:103
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、未分化星細胞腫の世界市場を広く調査・分析し、今後の市場展望をまとめております。未分化星細胞腫の種類別市場規模(手術、放射線、化学療法)、用途別市場規模(事前登録フェーズ、臨床試験フェーズ)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Genentech、EirGen Pharma、Pfizer、Isarna Therapeutics、Avid Bioservices、Axelar、Celldex Therapeutics、Novartis、Amgen、Boehringer Ingelheim
・地域別グローバル市場分析 2015年-2020年
・未分化星細胞腫の北米市場(アメリカ、カナダ、メキシコ)
・未分化星細胞腫のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・未分化星細胞腫のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・未分化星細胞腫の南米市場(ブラジル、アルゼンチン)
・未分化星細胞腫の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:手術、放射線、化学療法
・用途別分析:事前登録フェーズ、臨床試験フェーズ
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The global Anaplastic Astrocytoma market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Anaplastic Astrocytoma market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Anaplastic Astrocytoma market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Anaplastic Astrocytoma market has been segmented into:
Surgery
Radiation
Chemotherapy

By Application, Anaplastic Astrocytoma has been segmented into:
Pre-Registration Phase
Clinical Trail Phase

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Anaplastic Astrocytoma market presented in the report. This section sheds light on the sales growth of different regional and country-level Anaplastic Astrocytoma markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Anaplastic Astrocytoma market.

The report offers in-depth assessment of the growth and other aspects of the Anaplastic Astrocytoma market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Anaplastic Astrocytoma Market Share Analysis
Anaplastic Astrocytoma competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Anaplastic Astrocytoma sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Anaplastic Astrocytoma sales, revenue and market share for each player covered in this report.

The major players covered in Anaplastic Astrocytoma are:
Genentech
EirGen Pharma
Pfizer
Isarna Therapeutics
Avid Bioservices
Axelar
Celldex Therapeutics
Novartis
Amgen
Boehringer Ingelheim

【レポートの目次】

Table of Contents

1 Anaplastic Astrocytoma Market Overview
1.1 Product Overview and Scope of Anaplastic Astrocytoma
1.2 Classification of Anaplastic Astrocytoma by Type
1.2.1 Global Anaplastic Astrocytoma Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Anaplastic Astrocytoma Revenue Market Share by Type in 2019
1.2.3 Surgery
1.2.4 Radiation
1.2.5 Chemotherapy
1.3 Global Anaplastic Astrocytoma Market by Application
1.3.1 Overview: Global Anaplastic Astrocytoma Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Pre-Registration Phase
1.3.3 Clinical Trail Phase
1.4 Global Anaplastic Astrocytoma Market by Regions
1.4.1 Global Anaplastic Astrocytoma Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Anaplastic Astrocytoma (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Anaplastic Astrocytoma Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Anaplastic Astrocytoma Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Anaplastic Astrocytoma Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Anaplastic Astrocytoma Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Anaplastic Astrocytoma Status and Prospect (2015-2025)
2 Company Profiles
2.1 Genentech
2.1.1 Genentech Details
2.1.2 Genentech Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Genentech SWOT Analysis
2.1.4 Genentech Product and Services
2.1.5 Genentech Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.2 EirGen Pharma
2.2.1 EirGen Pharma Details
2.2.2 EirGen Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 EirGen Pharma SWOT Analysis
2.2.4 EirGen Pharma Product and Services
2.2.5 EirGen Pharma Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer SWOT Analysis
2.3.4 Pfizer Product and Services
2.3.5 Pfizer Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.4 Isarna Therapeutics
2.4.1 Isarna Therapeutics Details
2.4.2 Isarna Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Isarna Therapeutics SWOT Analysis
2.4.4 Isarna Therapeutics Product and Services
2.4.5 Isarna Therapeutics Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.5 Avid Bioservices
2.5.1 Avid Bioservices Details
2.5.2 Avid Bioservices Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Avid Bioservices SWOT Analysis
2.5.4 Avid Bioservices Product and Services
2.5.5 Avid Bioservices Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.6 Axelar
2.6.1 Axelar Details
2.6.2 Axelar Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Axelar SWOT Analysis
2.6.4 Axelar Product and Services
2.6.5 Axelar Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.7 Celldex Therapeutics
2.7.1 Celldex Therapeutics Details
2.7.2 Celldex Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Celldex Therapeutics SWOT Analysis
2.7.4 Celldex Therapeutics Product and Services
2.7.5 Celldex Therapeutics Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Novartis SWOT Analysis
2.8.4 Novartis Product and Services
2.8.5 Novartis Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Amgen SWOT Analysis
2.9.4 Amgen Product and Services
2.9.5 Amgen Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
2.10 Boehringer Ingelheim
2.10.1 Boehringer Ingelheim Details
2.10.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Boehringer Ingelheim SWOT Analysis
2.10.4 Boehringer Ingelheim Product and Services
2.10.5 Boehringer Ingelheim Anaplastic Astrocytoma Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Anaplastic Astrocytoma Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Anaplastic Astrocytoma Players Market Share
3.2.2 Top 10 Anaplastic Astrocytoma Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Anaplastic Astrocytoma Revenue and Market Share by Regions
4.2 North America Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
4.3 Europe Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
4.5 South America Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
5 North America Anaplastic Astrocytoma Revenue by Countries
5.1 North America Anaplastic Astrocytoma Revenue by Countries (2015-2020)
5.2 USA Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
5.3 Canada Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
5.4 Mexico Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
6 Europe Anaplastic Astrocytoma Revenue by Countries
6.1 Europe Anaplastic Astrocytoma Revenue by Countries (2015-2020)
6.2 Germany Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
6.3 UK Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
6.4 France Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
6.5 Russia Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
6.6 Italy Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Anaplastic Astrocytoma Revenue by Countries
7.1 Asia-Pacific Anaplastic Astrocytoma Revenue by Countries (2015-2020)
7.2 China Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
7.3 Japan Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
7.4 Korea Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
7.5 India Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
8 South America Anaplastic Astrocytoma Revenue by Countries
8.1 South America Anaplastic Astrocytoma Revenue by Countries (2015-2020)
8.2 Brazil Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
8.3 Argentina Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Anaplastic Astrocytoma by Countries
9.1 Middle East & Africa Anaplastic Astrocytoma Revenue by Countries (2015-2020)
9.2 Saudi Arabia Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
9.3 UAE Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
9.4 Egypt Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
9.5 South Africa Anaplastic Astrocytoma Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Anaplastic Astrocytoma Revenue and Market Share by Type (2015-2020)
10.2 Global Anaplastic Astrocytoma Market Forecast by Type (2019-2024)
10.3 Surgery Revenue Growth Rate (2015-2025)
10.4 Radiation Revenue Growth Rate (2015-2025)
10.5 Chemotherapy Revenue Growth Rate (2015-2025)
11 Global Anaplastic Astrocytoma Market Segment by Application
11.1 Global Anaplastic Astrocytoma Revenue Market Share by Application (2015-2020)
11.2 Anaplastic Astrocytoma Market Forecast by Application (2019-2024)
11.3 Pre-Registration Phase Revenue Growth (2015-2020)
11.4 Clinical Trail Phase Revenue Growth (2015-2020)
12 Global Anaplastic Astrocytoma Market Size Forecast (2021-2025)
12.1 Global Anaplastic Astrocytoma Market Size Forecast (2021-2025)
12.2 Global Anaplastic Astrocytoma Market Forecast by Regions (2021-2025)
12.3 North America Anaplastic Astrocytoma Revenue Market Forecast (2021-2025)
12.4 Europe Anaplastic Astrocytoma Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Anaplastic Astrocytoma Revenue Market Forecast (2021-2025)
12.6 South America Anaplastic Astrocytoma Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Anaplastic Astrocytoma Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

...

【掲載企業】

Genentech、EirGen Pharma、Pfizer、Isarna Therapeutics、Avid Bioservices、Axelar、Celldex Therapeutics、Novartis、Amgen、Boehringer Ingelheim

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の未分化星細胞腫市場2020年:企業別・地域別・種類別・用途別市場予測(~2025年)(Global Anaplastic Astrocytoma Market 2020 by Company, Regions, Type and Application, Forecast to 2025)]についてメールでお問い合わせはこちらでお願いします。